NCT04770272 2026-01-12
neoMono
Palleos Healthcare GmbH
Phase 2 Terminated
Clinical Trials
33 trialsNCT01358877 2025-11-28
APHINITY
Hoffmann-La Roche
Phase 3 Completed
NCT00630032 2024-02-21
TavIx
UNICANCER
Phase 3 Completed
NCT00841828 2023-03-31
Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients
Spanish Breast Cancer Research Group
Phase 2 Completed
NCT01036087 2023-03-30
Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02315196 2023-03-29
Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer
Rutgers, The State University of New Jersey
Phase 2 Active not recruiting
NCT01779050 2022-11-01
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells
Washington University School of Medicine
Phase 2 Terminated
NCT00087178 2022-08-11
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
NSABP Foundation Inc
Phase 3 Completed
NCT02050919 2022-03-21
Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma
OHSU Knight Cancer Institute
Phase 2 Completed
NCT03556358 2022-01-14
Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With HerceptinĀ® in HER2+ Early Breast Cancer
Tanvex BioPharma USA, Inc.
Phase 3 Completed
NCT00193206 2021-11-23
Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00193050 2021-10-26
Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00464646 2021-10-25
Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer
NSABP Foundation Inc
Phase 2 Completed
NCT00381706 2021-09-29
Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01593020 2021-09-22
Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01220128 2021-05-25
INDUCT
GlaxoSmithKline
Phase 2 Terminated
NCT00052910 2020-05-07
Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT01855828 2020-03-31
Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer
Yale University
Phase 2 Completed
NCT00513292 2019-01-23
Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT00215644 2018-11-02
MATRIX EG
Merck KGaA, Darmstadt, Germany
Phase 2 Completed
NCT02358863 2018-09-06
mEGA
Georgetown University
Phase NA Terminated
NCT00954512 2018-08-24
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT00559845 2018-04-09
A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT00950300 2018-01-23
A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT00176488 2017-03-23
Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT00499603 2016-11-01
Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Unknown
NCT00454636 2016-09-29
A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer.
Hoffmann-La Roche
Phase 2 Completed
NCT00429299 2016-03-22
CHERLOB
GlaxoSmithKline
Phase 2 Completed
NCT00322374 2016-03-10
Phase I Combination w/ Epirubicin
R-Pharm
Phase 1 Completed
NCT00737438 2016-02-03
Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00756470 2014-11-17
Phase II Neoadjuvant in Inflammatory Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00375999 2014-03-03
Docetaxel and Epirubicin in Advanced Gastric Cancer
Yonsei University
Phase 2 Completed
NCT00270894 2012-03-20
Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients
Accelerated Community Oncology Research Network
Phase 2 Completed